recombinant human rh cripto 1 (R&D Systems)
Structured Review
Recombinant Human Rh Cripto 1, supplied by R&D Systems, used in various techniques. Bioz Stars score: 93/100, based on 3 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/recombinant+human+cripto/Recombinant+Human+Cripto-1+Protein%2C+CF/pm38150919-133-0-4
Average 93 stars, based on 3 article reviews
Images
Related Articles
Enzyme-linked Immunosorbent Assay:Article Title: Sulforaphane Suppresses the Growth of Triple-negative Breast Cancer Stem-like Cells In vitro and In vivo Article Snippet: .. 276 277 ELISA studies 278 279 Recombinant:Article Title: Effects of a novel Nodal-targeting monoclonal antibody in melanoma Article Snippet: SPR analyses were performed on a Biacore 3000 instrument from GE Healthcare, using CM5 sensor chips and certified HBS buffer (20 mM HEPES, 0.15 M NaCl, pH 7.2, P20, 0.005%). .. Recombinant human Nodal ( rh Nodal) and Article Title: Recombinant humanized Fab fragments targeting the CFC domain of human Cripto-1. Article Snippet: In the era of immunotherapy, the targeting of disease-specific biomarkers goes hand in hand with the development of highly selective antibody-based reagents having optimal pharmacological/toxicological profiles.. One interesting and debated biomaker for several types of cancers is the onco-fetal protein Cripto-1 that is selectively expressed in many solid tumours and has been actively investigated as potential theranostic target.. Starting from previously described anti-CFC/Cripto-1 murine monoclonal antibodies, we have moved forward to prepare the humanized recombinant Fabs which have been engineered so as to bear an MTGase site useful for a one-step site-specific labelling. Concentration Assay:Article Title: Recombinant humanized Fab fragments targeting the CFC domain of human Cripto-1. Article Snippet: In the era of immunotherapy, the targeting of disease-specific biomarkers goes hand in hand with the development of highly selective antibody-based reagents having optimal pharmacological/toxicological profiles.. One interesting and debated biomaker for several types of cancers is the onco-fetal protein Cripto-1 that is selectively expressed in many solid tumours and has been actively investigated as potential theranostic target.. Starting from previously described anti-CFC/Cripto-1 murine monoclonal antibodies, we have moved forward to prepare the humanized recombinant Fabs which have been engineered so as to bear an MTGase site useful for a one-step site-specific labelling. |
